This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The biopharma company will be required to seek prior approval before acquiring related products. to address the potential competitive harm Amgen’s $27.8 We believe the government can protect competition while enhancing the value of biotech M&A activity,” John Delacourt, Deputy General Counsel for BIO declared.
The results could help Lilly differentiate its product from Novo Nordisk’s in the increasingly competitive market of obesity medications. The post Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test appeared first on MedCity News.
For 20 of the leading biopharmaceutical companies, the second quarter (Q2) of 2023 has brought an aggregate market capitalisation growth of 2.3 Q2 2023 biopharma market capitalisation results Eli Lilly “Eli Lilly witnessed the largest market capitalisation growth of 36.1 trillion in the Q1 of 2023 to $3.56 trillion in Q2 2023.
Sanofi breast cancer drug amcenestrant has failed in a Phase 3 clinical trial, leading the pharmaceutical giant to discontinue all clinical development of the small molecule. The move means Sanofi is out of the competitive chase to develop a so-called “oral SERD” therapy for patients with a certain type of breast cancer.
In Biopharma, where precision and accuracy are important, integrating robust processes is not just a necessity but a strategic imperative. Overreliance on automation can lead to complacency and blind trust in technology, leading to potential oversight of critical errors or deviations.
As professionals with more than a half-century between us working in biopharma and diagnostics marketing and communications from the corporate (Ayaz Malik) and agency (Sandra Stahl) sides, we believe nurturing multigenerational teams is an especially powerful yet underutilized strategy for our industry.
They also think Walgreens’ move could lead to greater competition, consolidation and innovation within the broader pharmacy industry. Experts think that this move could yield several strategic benefits, given the higher profit margins associated with specialty medications compared to traditional drugs.
Contineum Therapeutics plans to spend most of its IPO cash on clinical testing of a lead drug candidate in development for idiopathic pulmonary fibrosis and multiple sclerosis. This small molecule blocks a competitive target pursued by several other companies, including Bristol Myers Squibb and AbbVie.
Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. For biopharma, success in this space will require integrated models that are significantly different than what has been used with historic medicines. In oncology, it’s 47% less.
Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. Such inorganic growth is no longer viable, argues Pervaise Khan, Accenture’s UK Life Sciences Lead.
In the first 11 months of 2022, biopharma M&A value dropped by 42 percent compared to 2021, with Pfizer’s acquisition of Biohaven , the single largest deal up to December 2022. Alliances were a significant focus for biopharma and companies’ M&A strategies in 2022. Biopharma alone held over $1.4
As the biopharmaceutical industry grows more competitive, so too does the need for effective supply chain management. This higher level of interdependence is due to the rapid growth rate of technology development within the biopharma and pharmaceutical industries.
Influencing factors identified in the report include higher competition, competitive pricing and inflation rate, technological advancements and evolving regulatory guidelines. These factors have led to industry 4.0 technologies.
Together, these groups compile vast amounts of data, including rich information on patient populations, target customers, and the competitive landscape. Historically, competitive and market analysis data has been stored in spreadsheets. Truly understanding the competitive landscape and market environment.
This year, Clarivate acquired Bioinfogate , a leading provider of analytics solutions in the life sciences and producer of the OFF-X portal. OFF-X is already integrated with several Cortellis products, including Cortellis Drug Discovery Intelligence and Cortellis Competitive Intelligence.
In 2021, Novo Nordisk Pharmatech, a leading pharmaceutical-grade insulin and Quats product supplier announced plans to enter the enzyme market. That is a key competitive advantage,” says Laursen. “We The impact could be huge for the biopharma industry. Developing best-in-class speciality enzymes.
billion buyout of Principia Biopharma has run into trouble, after the FDA placed it on partial clinical hold while a safety signal is investigated. All the BTK inhibitors are designed to be able to cross the blood brain barrier and enter the central nervous system, dampening down the autoimmune response that leads to neuronal damage in MS.
At Roche at the time, his job was to lead a task force which was given the objective of planning a strategy to preserve and protect the companies billion-dollar originator biologics franchises as well as build a plan which would counter the introduction and use of biosimilars. Now, as the President of Accord BioPharma , the U.S.
The plans are profitable and continue to draw new Medicare enrollees, leading all top payers to make investments in retaining and attracting enrollees. Teaming with Walmart allows UnitedHealth to keep its leading position in the Medicare Advantage segment, where it holds the top market share with 7.9 2 Humana by more than 2.5
A just-published report from the Medicines Manufacturing Industry Partnership (MMIP) – set up by the UK government and biopharma industry in 2014 to drive growth in the category – says the sector has the potential to be a driver for the UK economy in the next decade.
Merck’s EyeBio acquisition brings a lead program ready for pivotal testing in diabetic macular edema. The therapy could pose competition to Eylea, the blockbuster Regeneron Pharmaceuticals eye drug. The post Merck Sees Pipeline Diversification Opportunity in $1.3B EyeBio Acquisition appeared first on MedCity News.
With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This allows for a complementary portfolio fit without the kind of competitive overlap that comes under regulatory scrutiny from the FTC.
However, if all products in the market are chasing the largest segment of that market, then this segment consequentially becomes the most competitive. Similarly for biopharma companies, if all products in a therapeutic class are pursuing the high decile HCPs, then these HCPs become the most competitive targets.
Increased competition and evolving standard of care New competitors are entering the market at a rapid pace, and competition is intensifying. This competitive intensity tends to focus on smaller patient populations with multiple treatment options (1,2). However, with rapid growth comes growing pains.
17, 2024 – FINN Partners, one of the world’s leading independent marketing and communications agencies, today announces the appointment of Julie Adrian as Managing Partner and UK Health Group Lead. In the newly created position, Adrian reports to Gil Bashe, Chair FINN Global Health and Purpose.
1 However, as most biosimilars are developed by means of a complex biotechnological process in living organisms, this inevitably leads to differences between the biosimilar and the reference product. Marie Manley leads Sidley’s Life Sciences team in London and is a distinguished thought leader and adviser on EU and UK regulatory law.
1 As revolutionary upstream and downstream technologies become a reality, biopharma companies will need to determine how best to integrate them into their current systems. 2 Capabilities in suspension cell lines and proprietary cell lines are becoming increasingly important to competitiveness within the gene therapy industry.
This alignment leads to smarter, more impactful HCP interactions. Based on this, the AI assistant could also suggest next steps, like sharing clinical evidence aligned with Dr. Smiths patients, a comparative study related to competitive products Dr. Smith has prescribed, or follow-up material to a webinar Dr. Smith attended.
With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience. In one survey, only 12% of HCPs said they felt biopharma companies are very effective at providing HCP education and training to them.
NEWS: Biopharma struggling to find talent with adequate digital skills Looking onward to 2028, the Skills report predicted that, out of a total 81 percent within the cell and gene therapy industry, roles will span support services, R&D and discovery, and bioprocessing.
The event is a key platform for global supply chain connections, offering unmatched opportunities to form partnerships, secure contracts, and stay competitive. However, the venture capital branches of leading pharmaceutical firms are proving to be innovation engines, vital in fostering advances and addressing key healthcare issues.
16,17 However, care must be taken to ensure that chemicals from biomass are not produced in competition with food production and do not have a negative impact on the environment or natural habitats. Production and value creation can be regionalised and decentralised, which could lead to a more resilient economic structure.
Lack of Data and/or Proxies There is typically little to no competitive data available With over 95% of the over 7,000 estimated rare diseases having no treatment, these products typically have no competition and thus no competitive data. Additionally, though claims data, ICD-11 codes, patient advocacy groups, etc.
The migration of these products and services into the Clarivate portfolio further bolster solutions that support pharmacovigilance medical literature monitoring, patent research, systematic review literature searches, MDR literature review searches, as well as competitive and business intelligence research.
Skip to a topic Axonis' journey and purpose The impact of the economic client on emerging biopharma The place of Artificial Intelligence in drug development & discovery Working with NASA Relationships with CROs, CDMOs, and other service providers What made you want to start Axonis? sending neurons to space.
As the pharmaceutical landscape grows more dynamic and competitive, life sciences companies are increasingly expected to develop more innovative brand launches, whilst juggling more complexity in marketing and interactions with healthcare professionals (HCPs).
In a fiercely competitive U.S. While marquee IDNs attract national headlines, these smaller systems reflect how markets are adjusting to an increasingly value-based and competitive landscape. ChristianaCare’s future expansion plans could escalate the competition between Highmark and UPMC. ChristianaCare, Wilmington, Delaware.
This article outlines how developers can utilize sustainability initiatives to boost revenue, reduce costs, and advance innovation, ensuring a strategic, long-term, and more sustainable position in today’s competitive landscape.
exclusions exist for orphan drug designation and biosimilar competition ). This post was written by Roy Moore, Senior Healthcare Research and Data Analyst, and Bill Melville, Lead Healthcare Research and Data Analyst The post Five points on CMS’s first ten picks for price negotiations appeared first on Clarivate.
After Walgreens upped its ownership stake in the primary-care company VillageMD from 30 to 63 percent and then announced plans to operate 1,000 clinics by 2027, the writing was on the wall: to stay competitive and manage costs in CVS’ newly integrated Aetna plan, CVS could benefit by making a larger bid for primary care of its own.
She has over 19 years of experience within Pharmaceutical R&D analytics and currently leads a broad array of assignments including Pharma R&D industry benchmarking, competitive landscape analysis and building business intelligence platforms within the R&D development space.
Clarivate leads two subscription-based pre-competitive consortia for Algorithm Benchmarking (ABC) and Computational Biology for Drug Discovery (CBDD) , where Clarivate benchmarks and implements advanced state-of-the-art pathway and network analysis algorithms that have a direct application in drug discovery and development.
Fruquintinib will face fierce competition should it be approved in the third- and later-line setting. The question of which KRAS inhibitor is most effective remains elusive, although being first to market in addition to strong efficacy and safety data could differentiate the more competitive agent.
The collaborative spirit arising between pharmaceutical and biotechnology companies is leading to a new rapport with regulators, as well. McCall sees the whole experience as a positive one for biopharma: “When I started in industry, this type of data sharing and collaboration was unheard of. It’s heartening.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content